Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel
Autor: | Yoshimasa Miyagawa, Ayako Bun, Yukie Fujimoto, Tomoko Higuchi, Hiromi Ozawa, Michiko Imamura, Yuichi Takatsuka, Kazuhiro Araki, Ayako Kira, Yasuo Miyoshi, Arisa Nishimukai |
---|---|
Rok vydání: | 2018 |
Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Paclitaxel Neutrophils medicine.medical_treatment Locally advanced Antineoplastic Agents Breast Neoplasms 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Albumins Internal medicine medicine Humans Lymphocyte Count Lymphocytes Progression-free survival Neutrophil to lymphocyte ratio Furans Aged Retrospective Studies Nab-paclitaxel Aged 80 and over Chemotherapy business.industry fungi Ketones Middle Aged medicine.disease Metastatic breast cancer Progression-Free Survival 030104 developmental biology chemistry 030220 oncology & carcinogenesis Female business Eribulin |
Zdroj: | Clinical Breast Cancer. 18:400-409 |
ISSN: | 1526-8209 |
Popis: | Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic factor for early-stage breast cancer, we investigated its usefulness in terms of the eribulin or nab-paclitaxel treatment efficacy for MBC.A total of 85 patients with MBC treated with eribulin (n = 59) or nab-paclitaxel (n = 26) were recruited. NLR values were collected at baseline, after 1 cycle, after 2 cycles, and at the end of treatment. The NLR cutoff value was set at 3.The progression-free survival (PFS) of patients with an NLR 3 at baseline (median, 242 days; n = 24) was significantly better than that of patients with an NLR of ≥ 3 (median, 98 days; n = 35; hazard ratio, 0.37, 95% confidence interval, 0.18-0.71; P = .0032). Similarly, the overall survival was marginally significantly better in patients with an NLR 3 who were treated with eribulin (P = .058). However, the NLR was not significantly associated with PFS or overall survival for patients treated with nab-paclitaxel. No significant association was found between the NLR during treatment and PFS in the eribulin group. The significance of the NLR for the efficacy of eribulin was consistent, irrespective of estrogen receptor status, previous anthracycline or endocrine use, and the number of previous chemotherapy regimens.A low NLR at baseline was significantly associated with improved PFS in patients treated with eribulin but not in those treated with nab-paclitaxel. Therefore, the baseline NLR might be clinically useful for selecting patients who would benefit from eribulin. |
Databáze: | OpenAIRE |
Externí odkaz: |